Nuvation Bio Reports Four-Year Median Response Duration for IBTROZI in ROS1+ NSCLC
Event summary
- Nuvation Bio to present updated IBTROZI (taletrectinib) data at AACR 2026, showing median DOR of 50 months in TKI-naïve ROS1+ NSCLC patients.
- Data includes nearly an additional year of follow-up from trials supporting IBTROZI's line-agnostic FDA approval in June 2025.
- Presentations will cover efficacy and safety in both TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC.
- TRUST-I and TRUST-II studies evaluated IBTROZI in 173 Chinese and 189 global patients respectively.
The big picture
Nuvation Bio's presentation at AACR 2026 underscores the growing importance of next-generation ROS1 inhibitors in treating advanced NSCLC. The extended follow-up data for IBTROZI comes at a time when precision oncology is increasingly focused on durable responses and CNS activity. The company's ability to demonstrate sustained efficacy could differentiate IBTROZI in a market dominated by established players like Pfizer's Lorlatinib.
What we're watching
- Clinical Efficacy
- How the unprecedented durability of IBTROZI's response will position it against existing ROS1 inhibitors in the market.
- Regulatory Strategy
- Whether Nuvation Bio can leverage these data to expand IBTROZI's indications or gain approvals in additional regions.
- Commercialization Pace
- The pace at which Nuvation Bio can convert clinical success into market share, particularly in the competitive ROS1+ NSCLC space.
Related topics